Sino Biopharmaceutical erhält in China Durchbruchstatus für zwei Hepatitis-B-Wirkstoffkandidaten
Valid market news retained in the public archive without immediate LiveCast distribution.
Valid market news retained in the public archive without immediate LiveCast distribution.